BTK inhibitors are associated with a lower risk of myeloid neoplasms and non-melanoma skin cancer compared with chemoimmunotherapy in chronic lymphocytic leukemia: a propensity score-matched analysis.
Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.